Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Gulamhusein, Aliya F., Hirschfield, Gideon M. · 2020 · Nature Reviews Gastroenterology & Hepatology

Abstract

Primary biliary cholangitis is a chronic, seropositive and female-predominant inflammatory and cholestatic liver disease, which has a variable rate of progression towards biliary cirrhosis. Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of next-generation therapy with licensed use of obeticholic acid or off-label fibrate derivatives for those with insufficient benefit from ursodeoxycholic acid, the current first-line drug. The disease biology spans genetic risk, epigenetic changes, dysregulated mucosal immunity and altered biliary epithelial cell function, all of which interact and arise in the context of ill-defined environmental triggers. A current focus of research on nuclear receptor pathway modulation that specifically and potently improves biliary excretion, reduces inflammation and attenuates fibrosis is redefining therapy. Patients are benefiting from pharmacological agonists of farnesoid X receptor and peroxisome proliferator-activated receptors. Immunotherapy remains a challenge, with a lack of target definition, pleiotropic immune pathways and an interplay between hepatic immune responses and cholestasis, wherein bile acid-induced inflammation and fibrosis are dominant clinically. The management of patient symptoms, particularly pruritus, is a notable goal reflected in the development of rational therapy with apical sodium-dependent bile acid transporter inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41575-019-0226-7

Cites

236 of 236 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 236 references

Research works printed but not linked: 1

  1. Cordell, H. J. et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat. Commun. 6, 8019 (2015). · DOI · Paper page

Cited by

See all 309

Metadata

Authors
Gulamhusein, A. F., & Hirschfield, G. M.
Affiliations
University Health Network (CA)
Corresponding author
Hirschfield, Gideon M.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2019-12-09
Volume
17
Issue
2
Pages
93-110
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W2993976670
Cited by
308
References
236
Citations by year
2026: 29 · 2025: 55 · 2024: 62 · 2023: 57 · 2022: 53 · 2021: 33 · 2020: 19
FWCI
3.45
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary biliary cirrhosis, pathogenesis, obeticholic acid, ursodeoxycholic acid, farnesoid X receptor, peroxisome proliferator-activated receptors, liver fibrosis, biliary cirrhosis, risk stratification, pruritus, nuclear receptor agonists, immunotherapy, cholestasis, cholangiocytes, epigenetic modifications
MeSH terms
Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Chenodeoxycholic Acid, Cholagogues and Choleretics, Environmental Exposure, Humans, Immunity, Innate, Liver Cirrhosis, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Autoimmunity, Receptors, Cytoplasmic and Nuclear, Disease Progression, Chloride-Bicarbonate Antiporters, Symporters, Organic Anion Transporters, Sodium-Dependent, MicroRNAs, Epigenesis, Genetic, Peroxisome Proliferator-Activated Receptors, Dihydrolipoyllysine-Residue Acetyltransferase, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary biliary cholangitis: pathogenesis and therapeutic opportunities. https://app.cochat.ai/papers/10.1038/s41575-019-0226-7
The paper
Gulamhusein, A. F., & Hirschfield, G. M. (2020). Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-019-0226-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.